Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
melatonin receptor agonist |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05CH03
|
| gptkbp:brand |
Hetlioz
|
| gptkbp:CASNumber |
609799-22-6
|
| gptkbp:developer |
gptkb:Vanda_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
1.3 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C15H19NO2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tasimelteon
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
MT1 and MT2 melatonin receptor agonist
|
| gptkbp:metabolism |
liver (CYP1A2, CYP3A4, CYP2C19)
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
elevated liver enzymes upper respiratory tract infection nightmares |
| gptkbp:synonym |
BMS-214778
|
| gptkbp:usedFor |
sleep disorders
non-24-hour sleep-wake disorder |
| gptkbp:bfsParent |
gptkb:MT1_receptor
|
| gptkbp:bfsLayer |
7
|